Skip to main content

Lineage Cell Therapeutics, Inc.

LCTX
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000876343

No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.

13F holders, Q4 2025

Institutional positions in Lineage Cell Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
123
+13 vs. Q3 2025
Shares held
101.7M
+13.8M (+15.7%) vs. Q3 2025
Total value
$169.8M
+$21.3M (+14.4%) vs. Q3 2025
New holders
25
29 more added
Sold out
12
28 more reduced

2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2025: 123 institutions
Q1 2021: 102 institutionsQ2 2021: 115 institutionsQ3 2021: 115 institutionsQ4 2021: 124 institutionsQ1 2022: 109 institutionsQ2 2022: 100 institutionsQ3 2022: 104 institutionsQ4 2022: 106 institutionsQ1 2023: 116 institutionsQ2 2023: 107 institutionsQ3 2023: 104 institutionsQ4 2023: 115 institutionsQ1 2024: 116 institutionsQ2 2024: 113 institutionsQ3 2024: 114 institutionsQ4 2024: 126 institutionsQ1 2025: 127 institutionsQ2 2025: 129 institutionsQ3 2025: 112 institutionsQ4 2025: 123 institutionsQ1 2026: 130 institutionsQ2 2026: 131 institutions
Value heldQ4 2025: $169.8M
Q1 2021: $141.8MQ2 2021: $208.5MQ3 2021: $191.7MQ4 2021: $182.0MQ1 2022: $112.3MQ2 2022: $102.7MQ3 2022: $73.1MQ4 2022: $76.2MQ1 2023: $104.7MQ2 2023: $106.6MQ3 2023: $89.1MQ4 2023: $82.5MQ1 2024: $138.3MQ2 2024: $94.2MQ3 2024: $85.6MQ4 2024: $53.8MQ1 2025: $49.7MQ2 2025: $88.4MQ3 2025: $148.6MQ4 2025: $169.8MQ1 2026: $176.5MQ2 2026: $152.7M
Institutions holding LCTX and their total value by quarter
QuarterHoldersValue
Q2 2026131$152.7M
Q1 2026130$176.5M
Q4 2025123$169.8M
Q3 2025112$148.6M
Q2 2025129$88.4M
Q1 2025127$49.7M
Q4 2024126$53.8M
Q3 2024114$85.6M
Q2 2024113$94.2M
Q1 2024116$138.3M
Q4 2023115$82.5M
Q3 2023104$89.1M
Q2 2023107$106.6M
Q1 2023116$104.7M
Q4 2022106$76.2M
Q3 2022104$73.1M
Q2 2022100$102.7M
Q1 2022109$112.3M
Q4 2021124$182.0M
Q3 2021115$191.7M
Q2 2021115$208.5M
Q1 2021102$141.8M

Institutions, Q4 2025

Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q3 2025.

Institutions holding LCTX in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
SEI Investments Co269,311$449.7K0.00%+269,311New
Omers Administration Corp283,200$472.9K0.00%+283,200New
Gsa Capital Partners LLP330,981$553.0K0.05%−339,875−50.7%Reduced
Barclays PLC348,510$582.0K0.00%+348,509+34,850,900.0%Added
EAM Investors, LLC442,221$738.5K0.08%00.0%Unchanged
Northern Trust Corp479,273$800.4K0.00%+35,921+8.1%Added
Citadel Advisors LLC507,052$846.8K0.00%+313,084+161.4%Added
Red Crane Wealth Management, LLC597,263$997.4K0.82%+85,900+16.8%Added
Susquehanna International Group, LLP706,415$1.18M0.00%+521,415+281.8%Added
Jane Street Group, LLC1,004,794$1.68M0.00%+859,931+593.6%Added
State Street Corp1,016,211$1.70M0.00%+60,589+6.3%Added
Marshall Wace, LLP1,362,061$2.27M0.00%+1,362,061New
Goldman Sachs Group Inc1,438,746$2.40M0.00%+1,294,070+894.5%Added
Morgan Stanley1,998,663$3.34M0.00%+992,212+98.6%Added
Millennium Management LLC2,110,419$3.52M0.00%−569,584−21.3%Reduced
Renaissance Technologies LLC2,404,800$4.02M0.01%+499,167+26.2%Added
Geode Capital Management, LLC2,461,193$4.11M0.00%+41,427+1.7%Added
BlackRock, Inc.3,834,113$6.40M0.00%+1,603,357+71.9%Added
Comerica Bank4,600,000$7.68M0.03%00.0%Unchanged
Raffles Associates LP5,362,788$8.96M6.72%−25,000−0.5%Reduced
Defender Capital, LLC.6,829,099$11.4M3.70%+6,829,099New
Vanguard Group Inc9,644,276$16.1M0.00%+637,346+7.1%Added
Broadwood Capital Inc49,560,992$82.8M5.00%00.0%Unchanged
Dauntless Investment Group, LLC0$00.00%−1,614,100−100.0%Sold out
Simplex Trading, LLC0$00.00%−28,017−100.0%Sold out
Dimensional Fund Advisors LP0$00.00%−27,121−100.0%Sold out
Citizens Financial Group Inc0$00.00%−15,000−100.0%Sold out
Beacon Capital Management, LLC0$00.00%−15,000−100.0%Sold out
R Squared Ltd0$00.00%−11,823−100.0%Sold out
AQR Capital Management LLC0$00.00%−11,650−100.0%Sold out
GWM Advisors LLC0$00.00%−11,500−100.0%Sold out
EverSource Wealth Advisors, LLC0$00.00%−288−100.0%Sold out
Wealthspire Advisors, LLC0$00.00%−88−100.0%Sold out
Steward Partners Investment Advisory, LLC0$00.00%−11−100.0%Sold out
Sound Income Strategies, LLC0$00.00%−4−100.0%Sold out
Point72 Asia (Singapore) Pte. Ltd.––––Not filed
Cubist Systematic Strategies, LLC––––Not filed